Utility of 18 F-FDG PET for Predicting Histopathologic Response in Esophageal Carcinoma following Chemoradiation
Andrea Arnett(Mayo Clinic), Christopher L. Hallemeier(Mayo Clinic in Arizona), Karthik Ravi(Mayo Clinic), Michael G. Haddock(Mayo Clinic in Arizona), Erica Martin Macintosh(Mayo Clinic), Kenneth W. Merrell(Mayo Clinic), Sarah E. James(Mayo Clinic), K. Robert Shen, Mark A. Nathan(Mayo Clinic), Michelle A. Neben Wittich(Mayo Clinic)
Cited by 34
Related Papers
Cholangiocarcinoma — evolving concepts and therapeutic strategies
|Nature Reviews Clinical Oncology|2017|1.7k
Factors Predicting Response, Perioperative Outcomes, and Survival Following Total Neoadjuvant Therapy for Borderline/Locally Advanced Pancreatic Cancer
|Annals of Surgery|2019|445
Adjuvant Radiotherapy and Chemotherapy for Pancreatic Carcinoma: The Mayo Clinic Experience (1975-2005)
|Journal of Clinical Oncology|2008|270
Oesophageal cancer
|The Lancet|2024|265